Hero image with Pittsburgh background pittplusme.org/study/1499

STUDY BASICS

Do you have HER2-positive breast cancer that has spread to the brain? If so, you may be eligible to participate in a research study to help find out if an investigational combination of drugs called ado-trastuzumab emtansine (also known as T-DM1 or Kadcyla®) and neratinib (also known as Nerlynx®) is safe and effective for people with HER2-positive breast cancer that has spread to the brain.


STUDY PURPOSE
Breast cancer that has spread to the brain can be difficult to treat. The purpose of this study is to help researchers find out if an investigational combination of drugs called ado-trastuzumab emtansine (also known as T-DM1 or Kadcyla®) and neratinib (also known as Nerlynx®) is a safe and effective treatment for people with HER2-positive breast cancer with brain metastases. Both medications have both been approved separately for use in people with breast cancer in other settings, but they are not specifically approved when given together for the treatment of breast cancer or breast cancer that has spread to the brain.
COULD THIS STUDY BE RIGHT FOR YOU?
  • Males and females ages 18 and up
  • Diagnosed with HER2-positive breast cancer that has spread to the brain

WHAT PARTICIPANTS CAN EXPECT
Participation involves an initial screening phase to find out if you are eligible for the study. If eligible, participants will be given neratinib tablets (160 mg) to take by mouth once per day and an injection of ado-trastuzumab emtansine once every 3 weeks. Tests and assessments during the study include physical exam, blood draws, electrocardiogram, echocardiogram, CT or MRI scan, and surveys.
IRB:
  STUDY19120240 - A Phase II Trial of HKI-272 (Neratinib), Neratinib and Capecitabine, and Neratinib and Ado-Trastuzumab Emtansine (T-DM1) for Patients with Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast cancer and Brain Metastases

Age Range
AGE:   18 and up

Duration DURATION:  Varies
VISITS:  Multiple

Location LOCATION: 
UPMC Magee-Womens Hospital
Compensation COMPENSATION: 

NONE

Phone Number PHONE NUMBER:
1-866-438-8230
SHARE STUDY
Printer Printer   Email A FriendEmail A Friend   ShareShare   TweetTweet   Linked-InLinked-In
Search Icon pittplusme.org/study/1499
OR
Phone Number PHONE NUMBER:
1-866-438-8230

MEET THE RESEARCHER


Adam Brufsky

Adam M. Brufsky, MD, PhD, is Associate Chief and Professor of Medicine in the Division of Hematology/Oncology in the Department of Medicine at the University of Pittsburgh and Associate Director of Clinical Investigation for the University of Pittsburgh Cancer Institute. Dr. Brufsky received his medical degree and doctorate from the University of Connecticut School of Medicine. He completed his residency in internal medicine at Brigham and Women's Hospital, Harvard Medical School and a fellowship in medical oncology and bone marrow transplantation at the Dana-Farber Cancer Institute.  Dr. Brufsky’s research interests include novel therapies for breast cancer, bone-breast cancer interactions and therapeutics, and the molecular biology of metastatic breast cancer.




PittPlusMe.org 1-866-438-8230 PittPlusMe@pitt.edu
@PittPlusMe share tweet